David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with <em>Targeted Oncology</em>at the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care. <br />
David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed withTargeted Oncologyat the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care.
Staying up-to-date with the latest advances in cancer care for optimal patient management is one of the key challenges that community oncologists face. Spigel notes that industry events, like the ASCO Annual Meeting, are important. These events are a source of new information on diagnostic and molecular advancements and changes in preferred cancer regimens that can simplify clinical practice and improve the quality of care for patients. Spigel explains that the ACCC is working to get these updates into the hands of community oncologists to uncomplicate cancer treatment for patients across the United States through education and advocacy.
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More